Dr. Tristram Bahnson provides an overview and discusses future directions for the care of patients with atrial fibrillation.
Duke Cardiology fellow Matt Sherwood interviews Dr. David Holmes on the PREVAIL trial results, embargo breaks, and how the WATCHMAN device will fare in the future. Get insights on this controversial issue at ACC.13.
Dr. Sana Al-Khatib presented on, “The Implantable Cardioverter-Defibrillator: Where Have We Been? Where Are We Going?”
We were delighted to have Duke alum Dr. Gust Bardy visit with us last week. He has previously helped conduct the landmark Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). His work with implantable defibrillators has continued wtih the development of an entirely subcutaneous ICD. He presented the fascinating story of its development last week at Duke Cardiology Grand Rounds.
US-based clinical registries, such as the National Cardiovascular Data Registry and Get With The Guidelines, have been instrumental in identifying and addressing gaps in quality of care for patients across the country. It is fascinating to see approaches in other countries who have developed nationwide clinical registries, inclusive of all citizens. In Sweden, clinical registries like SCAAR and SWEDEHEART, have not only been used to describe trends in nationwide clinical outcomes but are now being used as a platform for the conduct of randomized trials. With rich characterization of patients and longitudinal followup, clinical registries can be used to identify, enroll, and follow patients randomized to treatments or strategies of care that need more investigation. These innovative “randomized clinical registry studies” are being conducted in the US as well. We need more of them.
Dr. Jon Piccini discusses electrophysiology at ACC 2012 with cardiology fellow Ben Steinberg.
John chats with Zubin about his work in the NCDR-ICD registry. Zubin and his colleagues found that although rates of CRT implantation are improving in the overall population, disparities in care persist.
Download Zubin Eapen’s AHA.11 poster
Emil Fosbol discusses long-term safety and effectiveness of antithrombotic therapy in NSTEMI patients with prior atrial fibrillation.
Zubin Eapen and Dr. Rob Califf discuss ways to transform data into knowledge and the cross-disciplinary need for informatics.
Dr. Kenneth Mahaffey presented the eagerly awaited results from ROCKET AF, which showed that the new oral factor Xa inhibitor rivaroxaban met its primary efficacy end point of noninferiority to dose-adjusted warfarin with regard to all-cause stroke and non-central nervous system systemic embolism. Again, this was a packed session as you can see below.
Here are the ROCKET-AF slides presented by Dr. Mahaffey.